|
注册号: Registration number: |
ChiCTR2200066419 |
|
最近更新日期: Date of Last Refreshed on: |
2023-05-05 22:10:44 |
|
注册时间: Date of Registration: |
2022-12-05 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于综合干预体系减少中国老年患者术后综合并发症的多中心,前瞻性研究 |
|
Public title: |
A multicenter, prospective study of a comprehensive intervention-based system to reduce combined postoperative complications in elderly Chinese patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于综合干预体系减少中国老年患者术后综合并发症的多中心,前瞻性研究 |
|
Scientific title: |
A multicenter, prospective study of a comprehensive intervention-based system to reduce combined postoperative complications in elderly Chinese patients |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘畅 |
研究负责人: |
米卫东 |
|
Applicant: |
Liu Chang |
Study leader: |
Mi Weidong |
|
申请注册联系人电话: Applicant telephone: |
+86 18904089879 |
研究负责人电话:
Study leader's |
+86 13381082966 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
liuchang0121eason@163.com |
研究负责人电子邮件: Study leader's E-mail: |
wwdd1962@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
解放军总医院第一医学中心 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
|
|
申请注册联系人通讯地址: |
北京市海淀区复兴路28号解放军总医院 |
研究负责人通讯地址: |
北京市海淀区复兴路28号解放军总医院 |
|
Applicant address: |
28 Fuxing Road, Haidian District, Beijing, China |
Study leader's address: |
28 Fuxing Road, Haidian District, Beijing, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
解放军总医院第一医学中心 |
||
|
Applicant's institution: |
The First Medical Center, Chinese PLA General Hospital |
||
|
研究负责人所在单位: |
解放军总医院第一医学中心 |
||
|
Affiliation of the Leader: |
The First Medical Center, Chinese PLA General Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦审第S2022-577-01号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee Of Chinese PLA General Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-09-28 00:00:00 | ||
|
伦理委员会联系人: |
曹江 |
||
|
Contact Name of the ethic committee: |
Jiang Cao |
||
|
伦理委员会联系地址: |
北京市海淀区复兴路28号 |
||
|
Contact Address of the ethic committee: |
28 Fuxing Road, Haidian District, Beijing, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 010 66937166 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
解放军总医院第一医学中心 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Medical Center, Chinese PLA General Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号解放军总医院 |
||||||||||||||||||||||
|
Primary sponsor's address: |
28 Fuxing Road, Haidian District, Beijing, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
国家重点研发计划项目(2018YFC2001900) |
||||||||||||||||||||||
|
Source(s) of funding: |
National Key Research and Development Program of China(2018YFC2001900) |
||||||||||||||||||||||
|
研究疾病: |
术后综合并发症 |
||||||||||||||||||||||
|
Target disease: |
Comprehensive postoperative complications |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
本研究目的是在调查中国各医院术后并发症发生率的基础上,建立中国老年人群非心脏手术后术后综合并发症的发生率基线,并根据围手术期各系统并发症的综合干预体系方案,对五十余家医院的老年患者开展示范性综合干预,观察能否降低老年患者围手术期特殊危险事件的发生率和死亡率,改善其围手术期预后,提高生存质量进而验证并优化目前的评估系统和干预体系,为进一步广泛应用提供证据支持。 |
||||||||||||||||||||||
|
Objectives of Study: |
The purpose of this study was to establish a baseline of the incidence of comprehensive postoperative complications after non-cardiac surgery in the Chinese elderly population based on a survey of the incidence of postoperative complications in various hospitals in China, and to conduct a model comprehensive intervention for elderly patients in more than fifty hospitals based on a comprehensive intervention system protocol for perioperative complications of various systems to observe whether it can reduce the incidence of specific perioperative risk events and mortality in elderly patients, improve their perioperative prognosis, and improve the quality of survival thereby validating and optimizing the current assessment system and intervention system and providing evidence to support further widespread application. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.患者拒绝签署知情同意书 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. The patient refuses to sign the informed consent form |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-12-06 00:00:00至 To 2023-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-12-06 00:00:00 至 To 2023-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
N/A |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no sharing |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集和管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic Data Capture |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |